

Friday, DECEMBER 13, 2024 ~ Day 3 | MAIN SESSION

7:00 am Registration and Continental Breakfast

Stern Lobby

7:30 am Welcome and Introduction

Ash Tewari, MBBS, MCh

SESSION I | KEYNOTE LECTURE

7:40 am Cutting-edge Approaches in Kidney Cancer: Advances in Imaging Techniques and Innovative Minimally Invasive Treatments

Ketan Badani, MD

7:55 AM BREAK/ Intro to Live Case

SESSION II | LIVE CASE | Single Port (SP) Low Anterior Access Retroperitoneal Partial Nephrectomy

8:05 AM Surgeon: *Ketan Badani*

Moderator: *Alexandre Mottrie*

Panel: *Simone Crivellaro, Brian Shuch, Craig Rogers*

9:15 am BREAK / VISIT EXHIBITS

SESSION III | THE OPENING ACT: FROM SCREENING TO DIAGNOSIS TO SURVEILLANCE

Moderator: *Laurence Klotz*

Panel: *Ash Tewari, MBBS, MCh, Peter Pinto, Samir Taneja, Ming Zhou, Lalit Shah*

9:30 AM Business, economics, and regulations in urology

Deepak A. Kapoor, MD

9:45 AM Lancet Commission on Prostate Cancer

Nick James

10:00 AM Online Misinformation About Prostate Cancer

Stacy Loeb

10:15 AM Should we keep calling ISUP 1 Prostate Cancer?

Ming Zhou, MD, PhD

10:30 AM State-of-the-art lecture on Multicancer Early Detection

Eric Klein

10:45 AM How to Use Polygenic Risk Scores in Stratifying Patients for Prostate Cancer

Sujit Nair

11:00 AM Q&A

Moderator: *Eric Klein*

Panel: *Neal Shore, Mani Menon, Laurence Klotz, Mitchell Benson*

11:15 AM TP biopsy: The new standard of care

Jim Hu

- 11:30 AM Use of Testosterone Replacement Therapy in Patients on Active Surveillance and Post PCa Treatment**
Leon Telis
- 11:45 AM Active Surveillance: When to Intervene and the Role of Imaging and Genomics**
Peter Pinto
- 12:00 PM Genomics and clinical significance of MR visible vs invisible cancers**
Laurence Klotz
- 12:15 PM Use of Biplanar vs mpMRIs for Diagnosis of Early Prostate Cancer**
Samir S. Taneja
- 12:30 PM Use of PSMA in Active Surveillance Risk Stratification - HOLOGRAM**
Declan Murphy

12:45 PM LUNCH / VISIT EXHIBITS

SESSION V | EMERGING FRONTIERS IN METASTATIC AND ADVANCED PROSTATE CANCER

Moderator: *Natasha Kyprianou, MBBS, PhD*

Panel: *Himisha Beltran, Richard Stock, Sujit Nair, Mitchell Benson*

- 1:20 PM Update on prostatic intra-acinar neoplasia: precursors and beyond**
Angelo M. De Marzo
- 1:35 PM Emerging mechanisms of treatment resistance in advance prostate cancer**
Himisha Beltran
- 1:50 PM Biology of Prostate Cancer Metastases: Implications for Treatment**
Simpa Salami
- 2:05 PM Neoadjuvant apalutamide and downstaging prostate cancer**
Isaac Kim
- 2:20 PM Surgeon scientist journey in advanced prostate cancer**
Martin Gleave

2:35 PM Q&A

Moderator: *Isaac Kim, MD*

Panel: *Himisha Beltran, Richard Stock, Sujit Nair*

- 2:45 PM National Prostate Cancer Screening in Sweden**
Anna Lantz
- 3:00 PM German Prostate Cancer Screening Trial PROBASE**
Peter Albers
- 3:15 PM Oncological Outcomes after Lymph Node Dissection vs No LND for High Risk Prostate Cancer**
Peter Wiklund
- 3:30 PM Intensification versus De-Intensification Strategies in Prostate Cancer**
Neal Shore
- 3:45 PM Prostate Cancer: Navigating the landscape from HS to CRPC**
Cora Sternberg

SESSION V | Kidney

Moderator:	<i>Aditya Bagrodia</i>
Panel:	<i>Francesco Porpiglia , Alessandro Volpe, Todd Morgan, Michael Palese</i>
4:00 PM	The Evolving Management of Small Renal Masses: Advances in Active Surveillance and Future Perspectives <i>Craig Rogers</i>
4:15 PM	Mastering Surgical Skills: The Science of Proficiency-Based Progression Training <i>Alexandre Mottrie</i>
4:30 PM	Overview of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma <i>Brian Shuch</i>
4:45 PM	Modern Approach to Robotic Partial Nephrectomy for Hilar Tumors <i>Jihad Kaouk</i>
5:00 PM	Q&A
5:15 PM	Closing Remarks <i>Ketan Badani</i>

Friday, DECEMBER 13, 2024 ~ Day 3 | Breakout Sessions

ADVANCED PROSTATE CANCER TREATMENTS AND TRIALS

Moderator:	<i>Natasha Kyprianou, PhD</i>
Panel:	<i>Dimple Chakravarty, PhD, Martin Gleave, MD, Sujit Nair, PhD</i>
9:30 am	Racial Disparities in Advanced Prostate Cancer <i>Sanoj Punnen</i>
9:45 am	Genomic landscape of prostate cancer and implications for therapy selection <i>Gennady Bratslavsky</i>
10:00 am	Role of Theranostics and PARP Inhibitors <i>Cora Sternberg</i>
10:15 am	Updates in Neoadjuvant therapy trials for Prostate Cancer <i>Brian Chapin</i>
10:30 AM	Treatment de-escalation in metastatic hormone-sensitive PCa <i>Che-Kai Tsao</i>
10:45 AM	Translational analyses from STAMPEDE inc expression profiling (presented ESMO24) and also long term risk of fractures (ESMO 23 and EAU 23) <i>Nick James</i>
11:00 AM	Advanced staged PCa <i>Christina Jamieson</i>
11:15 AM	Q&A

FOCAL THERAPY OPTIONS FOR LOCALIZED PROSTATE CANCER

Moderator: *Daniel Eberli*

Panel: *Avinash Reddy*

11:45 AM **Pushing the Limits of Focal Therapy: How Much Pattern 4 is Acceptable?**

Art Rastinehad

12:00 PM **Why Cryotherapy is My Preferred Modality for Prostate Ablation**

Michael Gorin

12:15 PM **Q&A**

12:25 PM **BREAK/LUNCH/VISIT ABSTRACT SESSION**

KIDNEY BREAKOUT SESSION II: Exploring Kidney Cancer - Foundational Science to Clinical Insights

Moderator: *Ben Hopkins*

Panel: *Mehdi Mollapour, Natasha Kyprianou*

1:30 PM **RaPiDS in Kidney Cancer: Advancements in Drug Sensitivity Assessment and Future Directions**

Dr. Ben Hopkins

2:00 PM **Exploitation of metabolic pathways for therapeutic targeting of advanced renal cancer**

Dr. Roberto Pili

2:30 PM **Catalytic Inhibitors of Protein Phosphatases: A Path to Precision Kidney Cancer Therapy**

Dr. Mehdi Mollapour

3:00 PM **Advances in Kidney Cancer: Quantitative Ultrasound Innovations and Applications**

Dr. Jonathan Mamou

3:30 PM **Q&A**

3:50 PM **RETURN TO MAIN SESSION**